England & Company’s Post

The announcement of NuVasive's merger with Globus has brought both chaos and opportunity to the spinal device industry. While this may mean more challenges for many distributor partners, it also opens a world of possibilities and opportunities. At New Age Medical, we understand that rock-star reps are essential for success, and we’re proud to provide our team with reliable support, transparent compensation, and abundant growth opportunities. Find out how you can join us by emailing us at info@newagemedical.com. If you haven’t heard or read about the mega-merger, here’s a link. Let us know in the comments what YOU think about the merger. #megamerger #newagemedical #innovatingtheindustry #spinalimplants #spinesurgeons #distributorpartners #medicalsalesreps https://bit.ly/3YERBnr

Boston Scientific acquiring Silk Road Medical for $1.26B is big news. Why this matters for medtech innovators: 1. Capital returns: Successful exits like this enable medtech investors to realize returns. 2. Investment in innovation: With returns, there is stakeholder capital to reinvest in promising innovations, fueling the next wave of Medtech. 3. M&A Signaling: Positive signals from large strategics generate enthusiasm for future funding rounds and exits. 4. Capital supply chain activity: The entire capital supply chain is stimulated, promoting a healthy funding environment. The beautiful capital lifecycle rolls on. We love to see it.

In preparation for the holidays and trying to acquire as many presents as possible, I wrote about The Rules of Acquisition for medical device companies.   Medical Devices acquisitions are difficult and can lead to compliance issues. This article contains a list of useful Rules of Acquisition a company can take to ensure the acquisition is successful.

I read the post below from Joe Mullings about the increased M&A activity in med device and how the large strategic players are going to add companies to their portfolios.  I completely agree with his take, many people in our med device community are going to have their professional experience impacted by M&A in 2024.  Here are some thoughts on how to manage yourself and lead teams in this time of uncertainty. I have been part of companies that so desperately wanted to be bought they basically burned the boats in anticipation of a transaction.  I also lead a team that focused on not being bought. “Beat the number every quarter and our valuation will be so high no one will buy us” was one of our mantras.    It worked pretty well from my perspective. Interesting enough, the same exact approach to leadership works in both circumstances.  M&A, and all the rumors that go with it, is an enormous consumer of organizational energy and can be a disastrous distraction to a company. Hyper focus from a leadership team is the best antidote to keep your organization performing. A great litmus test to measure organizational focus is to determine when people start thinking about their own self interest and stop concentrating on the health and success of the business.  If you spend your time thinking about your job security, how much money you might make or what your next promotion might be, you are doing yourself and your team a disservice. I was with an organization that was purchased by a large strategic player and nearly every day the sales force would call each other and spend time speculating, time that should have been spent on what’s important, driving the business forward and spending time with your loved ones.  Self-interest is the killer of organizational productivity. If you are leading a team, managing your own territory or any part of a corporate team, your job is to focus on what you can do today to move the business forward.  It is a natural desire to be in the know, to have access to meetings or information that are interesting and outside the normal doldrums of our everyday responsibilities and to indulge in speculation, both positive and negative. It not sexy or overly appealing to focus on your job or your team instead of thinking about what might happen, but it’s a bedrock of great leadership and a world class team. You may have read some of my posts about “A” Players and how they act and think.  Top performers know how to focus, focus, focus on what is important now.  They control the controllable and don’t spend time worrying about things they cannot influence.  Two final thoughts. Performing well in times of uncertainty will distinguish you and present career opportunities you haven’t imagined.    Finally, people crave security in times of change.  BE A GREAT LEADER.  Exercise high communication, consistency in tone and demeanor, continual encouragement and relentless focus on the objective.  People will notice.

#Medtronic PLC (NYSE:MDT) shares moved higher in early trade on Tuesday as the medical devices company raised its fiscal 2024 sales and profit guidance. For the full year ending in April 2024, it expects organic revenue growth of 4.75% over fiscal 2023, up from its prior guidance of 4.5%. Adjusted earnings per share are expected to be in the range of $5.13 to $5.19, compared to prior guidance of $5.08 to $5.16. Both figures were higher than Wall Street expectations of year-over-year revenue growth of 2.9% to $32.13 billion and EPS of $5.12. The company’s 2Q fiscal 2024 results also topped expectations, with revenue rising 5.3% to $8 million, above the expected $7.91 billion. Adjusted EPS of $1.25 topped estimates of $1.18. The company benefitted from increased demand for its devices as surgery numbers rise, with it reporting a 7% year-over-year jump in its Medical Surgical segment for 2Q. More at #Proactive #ProactiveInvestors #NYSE #MDT http://ow.ly/FJGy1052Xvo

Check the latest divestment news from the industry for my followers ⤵️ 📣 Integra to buy J&J's Acclarent for $275M | MedTech Dive 📰 🎙️Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures. 🤔 It goes to show it's not always the top 🔟 globals 🌐 swallowing the smaller players sometimes the big guys need to take stock 📉 and carve off portfolios to keep at the head of their game 🔺 and "bargains" 💰 to be had for the next tier on the hunt for a solid M&A deal to strengthen their offering 💪. #latestnews #medicaldevice #healthcare #medtech #Acclarent #Integra #entsurgery #M&A #divestment

Check the latest divestment news from the industry for my followers ⤵️ 📣 Integra to buy J&J's Acclarent for $275M | MedTech Dive 📰 🎙️Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures. 🤔 It goes to show it's not always the top 🔟 globals 🌐 swallowing the smaller players sometimes the big guys need to take stock 📉 and carve off portfolios to keep at the head of their game 🔺 and "bargains" 💰 to be had for the next tier on the hunt for a solid M&A deal to strengthen their offering 💪. #latestnews #medicaldevice #healthcare #medtech #Acclarent #Integra #entsurgery #M&A #divestment

MedTech Mergers & Acquisitions are expected to see a big uptick in 2024 and 2025. Are Johnson & Johnson potentially looking to add to their big-ticket acquisitions in the #Cardiovascular space? This comes off the back of their $16B Abiomed aquisition in late 2022, potentially bolstering their presence in this high value market segment. I'm sure there's lots more exciting changes coming in the coming couple of years. Watch this space. https://lnkd.in/exniAkyz

Johnson & Johnson look to have their sights set on another major acquisition in Shockwave Medical. WSJ cited people familiar with the matter. They said the acquisition talks, if successful, could result in a finalized deal in the coming weeks. Another suitor could also seek a merger with Santa Clara, California–based Shockwave. Founded in 2009, Shockwave Medical has intravascular lithotripsy technology that uses sonic pressure waves to treat people with calcified arterial plaque. 2023 saw them bring in $489.7 million in revenue and their shares are trading 10 times higher than they were when the company initially went public in 2019. This isn’t the first time that Shockwave has been the subject of reports of a potential acquisition. Media reports last year mentioned Johnson & Johnson, Medtronic and Boston Scientific as potential suitors. #vidanews #medtech #medicaldevices #acquisition #cardiovascular

**Johnson & Johnson Q1 2024: Strong Start with Strategic Acquisitions Driving Growth 🚀** Q1 2024 has been robust for J&J, with earnings surpassing expectations at $2.71 per share, a 7 cent beat. Sales hit $21.4 billion, marking a 2.3% increase. The MedTech division shone with $7.8 billion in revenue, growing by 4.5%. The acquisition of Shockwave Medical strengthens J&J’s cardiovascular tech portfolio, promising enhanced long-term growth [oai_citation:1,J&J could reach market-leading medtech growth after consumer spinoff: analysts | MedTech Dive](https://lnkd.in/e5GbidJN). #HealthcareInnovation #MedTech #EarningsReport